NIPT Market in US Dominated by Sequenom
The market for non-invasive prenatal diagnostic tests in the US is dominated by Sequenom, which has the first mover advantage in the market. With around 45% market share in terms of volume of tests, Sequenom boasts of having effective marketing strategies that seek to encourage US physicians to recommend its MaterniT21 plus test. Ariosa, a tough competitor to Sequenom with respect to volume of tests performed in 2014, accounted for second highest share in the NIPT market. In 2014, Ariosa...
View full press release